• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Author
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Author "王文平" 2 results
        • Role of Contrast-Enhanced Ultrasonography in The Detection and Diagnosis of Small Primary Liver Cancer

          Objective To investigate the value of contrast-enhanced ultrasonography in detection and diagnosis of small primary liver cancer. Methods SonoVue-enhanced ultrasonography were performed on 353 patients with 378 primary liver cancer, less than 3 cm in diameter. Enhancement patterns and enhancement phases of hepatic lesions on contrast-enhanced ultrasonography were analyzed and compared with the results of histopathology. Results In all hepatic tumors, 96.6% (365/378) lesions enhanced in the arterial phase. Among them, 317 (83.9%) tumors enhanced earlier than liver parenchyma and 48 (12.7%) tumors enhanced synchronously with liver parenchyma, and 342 (90.5%) tumors showed early wash-out in the portal and late phases. With regard to the enhancement pattern, 329 (87.0%) tumors presented whole-lesion enhancement, 35 (9.3%) to be mosaic enhancement and 14 (3.7%) to be rim-like enhancement. If taking the whole-lesion enhancement and mosaic enhancement in arterial phase as diagnotic standard for primary liver cancer on contrast-enhanced ultrasonography, the sensitivity was 92.9%(351/378), and if the earlier or synchronous enhancement of the tumor compared with liver parenchyma in arterial phase and the wash-out in portal phase were regarded as the stardand, the sensitivity was 87.3%(330/378). Conclusion Contrast-enhanced ultrasonography could display real-time enhancement patterns as well as the wash-out processes both in hepatic tumors and the liver parenchyma. It might be of clinical value in diagnosis of primary liver cancer based on the hemodynamics of hepatic tumors on contrast-enhanced ultrasonography.

          Release date:2016-08-28 04:08 Export PDF Favorites Scan
        • 阿德福韋酯對乙型肝炎病毒e抗原陰性慢性乙型肝炎患者T細胞亞群的影響

          目的探討阿德福韋酯對乙型肝炎病毒e抗原(HBeAg)陰性慢性乙型肝炎患者外周血T細胞亞群的影響。 方法對2012年5月-2013年5月56例慢性乙型肝炎患者常規給予護肝治療,同時給予口服阿德福韋酯10 mg,1次/d,療程48周。檢測服藥前及48周后肝功能、乙型肝炎病毒(HBV) DNA及T細胞亞群。 結果經口服阿德福韋酯治療48周后,患者血清HBV-DNA滴度較治療前明顯下降,肝功能明顯改善,CD4+T淋巴細胞百分比(37.3%) 較治療前(32.8%) 明顯升高(P<0.001),CD4+/CD8+(1.37) 較治療前(1.11) 升高(P<0.005)。 結論阿德福韋酯治療HBeAg陰性慢性乙型肝炎,在抑制HBV的復制、減輕肝臟炎癥反應的同時,也可能改善了慢性乙型肝炎患者的細胞免疫功能。

          Release date: Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜